ALXN News and Press, Alexion Pharmaceuticals Inc. From 05/01/19

Read more ...

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...

Read more ...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Alexion Pharmaceuticals' ( ALXN -1.5% ) Ultomiris (ravulizumab) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis with clinical sym...

- Final European Commission decision anticipated in June 2019 - - ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients switching from SOLIRIS ® (eculizumab) - Alexion Pharmaceuticals, Inc. (NASDA...

Alexion Pharmaceuticals, Inc. (ALXN) Q1 2019 Results Earnings Conference Call April 25, 2019, 08:00 AM ET Company Participants Susan Altschuller - VP, IR Ludwig Hantson - CEO & Director Paul Clancy - EVP & CFO John Orloff - EVP and Head, Research & Development Bri...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...

Alexion Pharmaceuticals ( ALXN ) Q1 results : Revenues: $1,140.4M (+22.5%); Soliris: $962M (+20.2%); Ultomiris: $24.6M; Strensiq: $130.1M (+17.5%); Kanuma: $23.5M (+19.9%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ......

1Q19 total revenues of $1,140.4 million, a 23 percent increase over 1Q18 and a 26 percent volume increase 1Q19 GAAP diluted EPS of $2.61; non-GAAP diluted EPS of $2.39 Strong U.S. launch underway for ULTOMIRIS ® (ravulizumab-cwvz) in adults with paroxysmal noctural hemoglobin...

Mustang Bio, Inc. ( MBIO ) soared last Thursday after the very successful results of its gene therapy, MB-107, for X-linked Severe Combined Immunodeficiency, or X-SCID, were published in the New England Journal of Medicine. The therapy, licensed from the St. Jude Children's Research Hospital, ...